Abstract: Chemical compounds which interact inside the central water cavity of hemoglobin and bridge between the two .alpha. subunits can be used to allosterically modify hemoglobin towards tense and relaxed states. The functional groups employed are aldehydes and carboxylic acids, wherein the aldehydes form covalent bonds (schiff base) with amino acid residues of hemoglobin and the carboxylic acids form ionic bonds with amino acid residues of hemoglobin. Particularly useful compounds within the practice of this invention bond to the n-terminal valine of one .alpha. subunit of hemoglobin, and the lysine 99 and/or arginine 141 of the other .alpha. subunit.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: Allosteric hemoglobin modifier compounds having the general structural formula: ##STR1## wherein the R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 moieties may be hydrogen, halogen or alkyl groups and may be the same or different, and wherein the R.sub.7 and R.sub.8 moieties may be hydrogen or methyl groups and may be the same or different.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: Compounds of the general structural formula: ##STR1## wherein X, Y and Z may each be CH.sub.2, NH, or O, R.sub.2-6 are either hydrogen, halogen, or a substituted or unsubstituted C.sub.1, C.sub.2, or C.sub.3 alkyl group and these moieties maybe the same or different, or alkyl moieties of aliphatic or aromatic rings incorporating two of the R.sub.2-6 sites, R.sub.7-8 are hydrogen, methyl, or ethyl groups and these moieties may be the same or different, or alkyl moieties as part of an aliphatic ring connecting R.sub.7 and R.sub.8, and R.sub.9 is a hydrogen, loweralkyl such as methyl, ethyl or propyl, or a salt cation such as sodium, potassium, or ammonium are useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: Allosteric hemoglobin modifier compounds having the general formula ##STR1## wherein X and Z may be CH.sub.2, NH or O.

Abstract: A method of treating a person for sickle cell anemia including administering to the patient's blood a therapeutically effective dosage of ethacrynic acid. The dosage may be administered to blood removed from the patient which blood after addition of the compound is restored to the patient or by other means such as orally.

Abstract: The present invention describes novel tritium labelled nitrogen mustard type compounds, and their aziridinium type analog, and a process for the production of same. The compounds are of value in medical research and development and also as active ingredients of pharmaceutical compositions. The compounds can be used to develop analogs of human disease states and can also be used to evaluate the mechanism of neurotransmitter regulation and function, both in vitro and in vivo.

Abstract: The present invention is directed to compounds of the general formula I and pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sup.1 =HO or HOOC(CH.sub.2).sub.x CHR.sup.2 NH--;R.sup.2 =H, lower alkyl, benzyl or --CH.sub.2 OH;x=0 or 1;A=--(CH.sub.2).sub.n -- or ##STR2## n=1 to 5; and Y=H, Cl or OCH.sub.3Z=H or Clm=0 or 1R=lower alkyl;with the proviso that where R.sup.1 =OH, Y is H or Cl and m is 1, n is 4 or 5.The present invention is also directed to an antisickling pharmaceutical carrier and an antisickling agent of the general formula (I) (without the proviso) and pharmaceutically acceptable salts thereof.

Abstract: The present invention is directed to a method of treating a person for sickle cell anemia comprising administering to the person a therapeutically effective dosage of a compound of the general formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: R=ethyl, propyl or isopropyl; and ##STR2##

Abstract: The present invention is directed to compounds of the general formula I and pharmaceutically acceptable salts thereof: ##STR1## wherein: R=ethyl, propyl or isopropyl; andA=(CH.sub.2).sub.n wherein n is 2, 4 or 5, and C(CH.sub.2).sub.3.

Abstract: A method of treating a person for sickle cell anemia including administering to the person a therapeutically effective dosage of the compound ##STR1## wherein at least one R=Cl, BR, CH.sub.3 or OCH.sub.3 and each other R=H, R'=H or CH.sub.3 and n=1, 2, 3, 4 or 5. The compound is preferably selected from the group consisting of clofibrate, clofibric acid, p-chlorophenoxyacetic acid and phenoxyacetic acid. It is preferably administered in solid dosage form and may advantageously be employed in prophylactic treatment to resist sickle cell crises.

Abstract: The present invention is directed to compounds of the general formula I and pharmaceutically acceptable salts thereof: ##STR1## wherein R=H or lower alkyl;R'=H, lower alkyl, benzyl, CH.sub.2 OH;A=(CH.sub.2).sub.1 to 5, >C(CH.sub.3).sub.2, >C (CH.sub.2).sub.3 ; andX=0 or 1.The present invention is also directed to a method of treating a person for sickle cell anemia comprising administering to the person a therapeutically effective dosage of the above compounds.In addition the invention includes the novel compound: ##STR2## which is inaccessible by synthetic procedures previously described for this general class of compounds.

Abstract: A method of treating a person for sickle cell anemia including administering a therapeutically effective dosage of the compound ##STR1## wherein at least one R=Cl, Br, CH.sub.3 or OCH.sub.3 and all the remaining R=H, R'=H or CH.sub.3 and n=1, 2, 3, 4 or 5. Among the preferred species are p-bromobenzyloxyacetic acid, 2-(p-bromobenzyloxy)-2-methylpropionic acid and 3, 4 dichlorobenzyloxyacetic acid. The compound 2-(p-bromobenzyloxy)-2-methylpropionic acid or 3,4 dichlorobenzyloxyacetic acid. The same compound provided as a pharmaceutical in unit dosage form and having properties of resisting the aggregation of hemoglobin in a sickle cell anemia patient.